Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131,553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of CDK12 alterations in a pan-cancer database.
Pan E, Cabal A, Javier-DesLoges J, Patel D, Panian J, Lee S, Shaya J, Nonato T, Xu X, Stewart T, Rose B, Shabaik A, Cohen E, Kurzrock R, Tamayo P, McKay RR. Pan E, et al. Among authors: lee s. Cancer Med. 2022 Feb;11(3):753-763. doi: 10.1002/cam4.4483. Epub 2021 Dec 12. Cancer Med. 2022. PMID: 34898046 Free PMC article.
Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.
Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. Kato S, et al. Among authors: lee s. JCO Precis Oncol. 2019;3:PO.18.00180. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22. JCO Precis Oncol. 2019. PMID: 31058253 Free PMC article.
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. Kato S, et al. Among authors: lee s. Oncoimmunology. 2020 Feb 17;9(1):1708065. doi: 10.1080/2162402X.2019.1708065. eCollection 2020. Oncoimmunology. 2020. PMID: 32117584 Free PMC article.
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers.
Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. Riviere P, et al. Among authors: lee s. Mol Cancer Ther. 2020 Oct;19(10):2139-2145. doi: 10.1158/1535-7163.MCT-20-0161. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747422 Free PMC article.
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. Kato S, et al. Among authors: lee s. Nat Commun. 2020 Oct 2;11(1):4965. doi: 10.1038/s41467-020-18613-3. Nat Commun. 2020. PMID: 33009371 Free PMC article.
131,553 results
You have reached the last available page of results. Please see the User Guide for more information.